SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

BTX RSS Feed
Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/19/2017 7:25:12 AM - Followers: 71 - Board type: Free - Posts Today: 0

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

BTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX News: BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017 07/20/2017 07:00:00 AM
BTX News: Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual ... 07/19/2017 07:00:00 AM
BTX News: Revised Proxy Soliciting Materials (definitive) (defr14a) 07/13/2017 05:31:50 PM
BTX News: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 07/13/2017 07:00:00 AM
BTX News: Statement of Changes in Beneficial Ownership (4) 07/12/2017 07:27:27 PM
PostSubject
#696   #OpRegen by Biotime $BTX: Adi2 07/19/17 07:25:12 AM
#695   I have been doing that and sold my ahab333 07/18/17 03:57:12 PM
#694   It's the pattern it trades. If you want Adi2 07/18/17 03:24:09 PM
#693   ADi2, do you know why shares of BTX ahab333 07/18/17 02:41:39 PM
#692   $BTX – OpRegen to be introduced to institutional Adi2 07/18/17 07:11:00 AM
#691   $BTX DD links for AST-OPC1 Adi2 07/17/17 09:43:18 AM
#690   News out on 5th patient enrolled and injected ahab333 07/17/17 09:22:00 AM
#689   More data, video, coming from ageX, Biotime, $BTX: Adi2 07/13/17 09:34:32 AM
#688   $BTX news: Asterias, Sub, provides an update about AST-OPC1: Adi2 07/12/17 07:45:53 AM
#687   Thanks for taking the time with your reply. Craig305 07/12/17 05:34:03 AM
#686   The investment Thesis with BioTime is that this Adi2 07/12/17 05:19:59 AM
#685   What is the next catalyst to move SP? Craig305 07/11/17 01:10:28 PM
#684   Here's another form 4 just emailed to me: ahab333 07/05/17 07:44:15 PM
#683   Form 4 today: looks like 20,000 common shares ahab333 07/05/17 07:32:29 PM
#682   Market Trends & What's happening out there, In Adi2 06/26/17 11:31:57 PM
#681   Priceless insight Adi. Much appreciated. I can foresee tjcunn 06/25/17 02:03:04 PM
#680   Switching from alternatives to Revenia is worth a discussion. Adi2 06/25/17 03:31:33 AM
#679   That's actually a very good sign. Means the Adi2 06/24/17 03:19:49 PM
#678   Good question. I'd be interested to hear some Perkin78 06/24/17 10:51:48 AM
#677   Quick article about a regenerative medicine startup that Perkin78 06/24/17 10:38:51 AM
#676   $BTX Investor presentation covering Renevia and AMD Therapy. Adi2 06/24/17 06:17:26 AM
#675   Adi -- Your DD and willingness to share tjcunn 06/23/17 09:51:26 PM
#674   Busy Day. BTX takes out partners (Hadasit HBL) Adi2 06/19/17 08:07:29 AM
#673   Biotime Expands & Advances Ophthalmology Portfolio Adi2 06/19/17 07:17:45 AM
#672   “… there are wolves out there that love Adi2 06/19/17 05:46:38 AM
#671   For the record only, Adi, an unschooled physicist terry hallinan 06/18/17 05:50:27 PM
#670   The Investment Thesis for Biotime $BTX: Adi2 06/18/17 03:00:58 AM
#669   Thanks Adi, I am here for the long ahab333 06/16/17 02:59:27 PM
#668   This is a non profit development corp. Currently, Adi2 06/16/17 02:34:30 PM
#667   What's with all the selling here yesterday and ahab333 06/16/17 02:04:18 PM
#666   Cosmetics, for non medical applications is rarely covered Adi2 06/16/17 12:56:20 AM
#665   I know that BTX is a real long ahab333 06/15/17 01:45:41 PM
#664   Thx Adi for the great summary of the tjcunn 06/15/17 12:52:27 PM
#663   There is some minor trading going on with Adi2 06/15/17 05:25:50 AM
#662   Notes of $BTX Renevia Pivotal Data Conference Call 14.6.2017 Adi2 06/15/17 05:12:56 AM
#661   Thanks. That's good with me too. Lingering down Perkin78 06/14/17 02:17:16 PM
#660   Perkin, 3.00 looks more like stronger support IMO ahab333 06/14/17 01:44:51 PM
#659   Started a long position just now. $3.10 support Perkin78 06/14/17 01:41:18 PM
#658   Renevia is Done. CE mark 2017, marketing starts Adi2 06/14/17 10:50:14 AM
#657   Renevia's Pivotal trial results are successful! CE mark Adi2 06/14/17 10:47:36 AM
#656   Renevia is Done. CE mark 2017, marketing starts Adi2 06/14/17 10:46:32 AM
#655   Crash, I believe tomorrow's update will be telling ahab333 06/13/17 11:50:27 PM
#654   And on very healthy volume. A good crashco 06/13/17 10:27:14 PM
#653   No one talking about the rise in shares ahab333 06/13/17 03:45:22 PM
#652   Thanks Adi and Terry for replies and concur tjcunn 06/11/17 05:36:58 PM
#651   These things are material information and need to Adi2 06/11/17 08:35:29 AM
#650   TJCunn, Obviously BTX thinks there is some redeeming value terry hallinan 06/11/17 12:59:01 AM
#649   BTX will announce top line results of Renevia tjcunn 06/08/17 09:54:13 PM
#648   BTX will announce top line results of Renevia tjcunn 06/08/17 09:54:00 PM
#647   Correct, they speak of 4+ billion TAM , Adi2 05/23/17 12:00:54 PM
PostSubject